【参考文献】 [1] Renzulli A,Carozza A,Romano G,et al.Recurrent infective endocarditis:a multivariate analysis of 21 years of experience. arenzul@tin.it[J].Ann Thorac Surg,2001,72(1):39-43. [2] 祝利华,张伟文,王舜尧,等.心脏外科手术后下呼吸道感染的高危因素分析[J].实用医学杂志, 2010,26(8):1379-1380. [3] 刘苏,陈淑敏,李晓恒,等.10年心脏手术后感染调查分析[J].中华医院感染学杂志,2003,13(5):433-435. [4] Hill GE,Frawley WH,Griffith KE,et al.Allogeneic blood transfusion increases the risk of postoperative bacterial infection:a meta-analysis[J].J Trauma,2003,54(5):908-914. [5] Banbury MK,Brizzio ME,Rajeswaran J,et al.Transfusion increases the risk of postoperative infection after cardiovascular surgery[J].J Am Coll Surg,2006,202(1):131-138. [6] Walz JM,Paterson CA,Seligowski JM,et al.Surgical site infection following bowel surgery:a retrospective analysis of 1446 patients[J].Arch Surg,2006,141(10):1014-1018. [7] Tartter PI,Quintero S,Barron DM.Perioperative blood transfusion associated with infectious complications after colorectal cancer operations[J].Am J Surg,1986,152(5):479-482. [8] 刘景汉,欧阳锡林.去白细胞输血基础和临床应用研究进展[J].中国输血杂志,2001,14(4):252-255. [9] Klos M,Korsak J.Immunomodulatory effect of blood components transfusions[J].Pol Merkur Lekarski,2002,13(77):413-416. [10] Osman HK,Peiris JS,Taylor CE,et al."Cytomegalovirus disease" in renal allograft recipients:is human herpesvirus 7 a co-factor for disease progression?[J].J Med Virol,1996, 48(4):295-301. [11] Nielsen HJ,Reimert CM,Dybkjaer E,et al.Bioactive substance accumulation and septic complications in a burn trauma patient:effect of perioperative blood transfusion?[J].Burns,1997,23(1):59-63. [12] 刘正敏,高新谱,韩雪莹.不同储存时间后过滤白细胞对浓缩红细胞临床疗效的影响[J].中国输血杂志,2003, 16(3):182-183. [13] 符晓阳,袁记,杨金华.胃肠道肿瘤患者围手术期输血与术后感染的关系[J].河南外科学杂志,2005,11(1):45. [14] Lu JC,Grayson AD,Jha P,et al.Risk factors for sternal wound infection and mid-term survival following coronary artery bypass surgery[J].Eur J Cardiothorac Surg,2003,23(6):943-949. [15] Grossi EA,Culliford AT,Krieger KH,et al.A survey of 77 major infectious complications of median sternotomy:a review of 7,949 consecutive operative procedures[J].Ann Thorac Surg,1985,40(3):214-223. [16] 周晔,刘冰,王建华,等.心脏外科重症监护病房患者医院感染鲍氏不动杆菌及耐药性分析[J].中华医院感染学杂志,2010,20(5):725-726. [17] Moskowitz DM,Klein JJ,Shander A,et al.Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center[J].Ann Thorac Surg,2004,77(2):626-634. [18] Purkayastha S,Athanasiou T,Malinovski V,et al.Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis[J].Heart,2006,92(4):531-532. [19] Eisen A,Giugliano RP.Antiplatelet and anticoagulation treatment in patients with non ST-segment elevation acute coronary syndrome:comparison of the updated North American and European guidelines[J].Cardiol Rev,2015.[Epub ahead of print] [20] Barbieri L,Pergolini P,Verdoia M,et al.Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor[J].Vascul Pharmacol,2015,11(1):31-36. [21] Ratliff TM,Hodge AB,Preston TJ,et al.Bloodless pediatric cardiopulmonary bypass for a 3.2-kg patient whose parents are of Jehovah′s Witness faith[J].J Extra Corpor Technol,2014,46(2):173-176. [22] Durandy Y.Perfusionist strategies for blood conservation in pediatric cardiac surgery[J].World J Cardiol,2010,2(2):27-33. [23] Corwin HL,Gettinger A,Fabian TC,et al.Efficacy and safety of epoetin alfa in critically ill patients[J].N Engl J Med,2007,357(10):965-976. [24] Schved JF.Preoperative autologous blood donation:a therapy that needs to be scientifically evaluated[J].Transfus Clin Biol,2005,12(5):365-369. [25] Mondal NK,Sorensen EN,Pham SM,et al.Systemic inflammatory response syndrome in end-stage heart failure patients following continuous-flow left ventricular assist device implantation:differences in plasma redox status and leukocyte activation[J].Artif Organs,2015,22(2):89-91. [26] Chryssos A,Stroup SJ,Pifer MM,et al.Management of heparin-resistant patients with benefits Maximizing biocompatibility in cardiopulmonary bypass:combining ATrynR recombinant antithrombin Ⅲ and CarmedaRheparinbonded perfusion circuits:a case series[J].J Extra Corpor Technol,2015,47(1):44-47. [27] Aldea GS,Doursounian M,O′Gara P,et al.Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG:a prospective,randomized study[J].Ann Thorac Surg,1996,62(2):410-417. [28] Gunaydin S,Farsak B,Mccusker K,et al.Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization[J].J Cardiovasc Med (Hagerstown),2009,10(2):135-142. [29] Ferraris VA,Ferraris SP,Saha SP,et al.Perioperative blood transfusion and blood conservation in cardiac surgery:the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline[J].Ann Thorac Surg,2007,83(5 Suppl):S27-S86. [30] Balachandran S,Cross MH,Karthikeyan S,et al.Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion after coronary artery surgery[J].Ann Thorac Surg,2002,73(6):1912-1918. [31] Ranucci M,Biagioli B,Scolletta S,et al.Lowest hematocrit on cardiopulmonary bypass impairs the outcome in coronary surgery:an Italian multicenter study from the National Cardioanesthesia Database[J].Tex Heart Inst J,2006,33(3):300-305. [32] Habib RH,Zacharias A,Schwann TA,et al.Adverse effects of low hematocrit during cardiopulmonary bypass in the adult:should current practice be changed?[J].J Thorac Cardiovasc Surg,2003,125(6):1438-1450. [33] Fergusson DA,Hebert PC,Mazer CD,et al.A comparison of aprotinin and lysine analogues in high-risk cardiac surgery[J].N Engl J Med,2008,358(22):2319-2331. [34] Myles PS,Thompson G,Fedorow C,et al.Evaluation of differences in patient and physician perception of benefit and risks of aspirin and antifibrinolytic therapy in cardiac surgery[J].Anaesth Intensive Care,2014,42(5):592-598. [35] Vander S T,Kaur S,Lancey R A,et al.Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid[J].J Thorac Cardiovasc Surg,1996,112(4):1098-1107. [36] Huang F,Wu Y,Yin Z,et al.A systematic review and meta-analysis of the use of antifibrinolytic agents in total hip arthroplasty[J].Hip Int,2015,25(6):502-509. [37] Mongan PD,Brown RS,Thwaites BK.Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization[J].Anesth Analg,1998,87(2):258-265. [38] Eaton MP.Antifibrinolytic therapy in surgery for congenital heart disease[J].Anesth Analg,2008,106(4):1087-1100. [39] Ichikawa J,Kodaka M,Kitahara T,et al.The use of thromboelastometry and tranexamic acid reduces blood loss and transfusion requirements in cardiac surgery under cardiopulmonary bypass[J].Masui,2015,64(2):131-138. [40] Koscielny J,von Tempelhoff GF,Ziemer S,et al.A practical concept for preoperative management of patients with impaired primary hemostasis[J].Clin Appl Thromb Hemost,2004,10(2):155-166. |